ReviewCurrent oncology (Toronto, Ont.)2026

Pragmatic Management of EGFR-Mutant NSCLC After Progression on Osimertinib: Canadian Expert Perspectives.

Nathalie Daaboul et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.